The Presidential Office today announced the winners of the 6th Presidential Innovation Award. Bora emerged from over 250 contenders, recognized for its innovative achievements that help domestic and international pharmaceutical companies shorten development timelines, reduce production costs, and accelerate time-to-market, thereby benefiting people worldwide. Bora received the Presidential Innovation Award – Service Innovation (Group Category), becoming the first pharmaceutical company ever to win this honor.
The Presidential Innovation Award, bestowed in the name of the head of state, is the highest national honor recognizing and encouraging “innovation.” The award celebrates contributions in products, technology, management, services, and culture, highlighting innovations that have a profound impact on the economy, society, and people’s well-being, while enhancing national development and strengthening Taiwan’s international competitiveness.
Bora Group Chairman, Bobby Sheng, stated:
“Talking about innovation is easy, but doing innovation is the real challenge. Today, I am both pleased and honored to share this distinction with all Bora colleagues. By combining agile ways of thinking to tackle diverse challenges with strong willpower and perseverance, we have built the largest CDMO (Contract Development and Manufacturing Organization) in Taiwan’s biotech and pharmaceutical industry. This achievement is leading Taiwan’s pharmaceutical industry toward internationalization and into the global arena. Bora’s mission is to elevate Taiwan’s influence in the global pharmaceutical market—we want the world to see the medicines made in Taiwan.”
Amid the rapid growth of the global healthcare industry, outsourcing in pharmaceutical manufacturing has become an inevitable trend. Leveraging Taiwan’s existing advantages and service-oriented spirit in contract manufacturing, Bora has pursued a dual-track growth strategy of organic expansion and external acquisitions. By centering on R&D capabilities and process technologies, Bora provides production capacity and contract services that help both domestic and international pharmaceutical companies shorten regulatory submission timelines. Through seven successful innovative acquisitions worldwide within just ten years, Bora has become the only company in Taiwan capable of providing both small-molecule and large-molecule CDMO services, while also entering the global supply chain of the world’s top five pharmaceutical companies.
Furthermore, this month Bora Group officially completed the acquisition of U.S.-based Upsher-Smith, a century-old pharmaceutical company, instantly becoming one of the largest manufacturers of oral solid dosage forms in the United States. By acquiring greater-scale capacity, Bora will continue expanding its operations and technical scope, reinforcing its leadership as Taiwan’s CDMO pharmaceutical pioneer—growing from local roots to a global presence.
Chairman Sheng added:
“Bora is a people-centric enterprise. Beyond our continued pursuit of innovation, we are also committed to practicing sustainable corporate social responsibility—giving back to society what we have gained from it. We will donate the entire prize money from this award to support hospitals and families affected by the recent Hualien earthquake, with the hope of accelerating reconstruction efforts so that communities and homes can recover as soon as possible.”
